Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium

Alzheimer's and Dementia

Volumn 9, Issue 2, 2013, Pages 137-140

  Carrillo, Maria C ^a   Blennow, Kaj ^b   Soares, Holly ^c   Lewczuk, Piotr ^d   Mattsson, Niklas ^b   Oberoi, Pankaj ^e   Umek, Robert ^e   Vandijck, Manu ^f   Salamone, Salvatore ^g   Bittner, Tobias ^h   Shaw, Leslie M ⁱ   Stephenson, Diane ^j   Bain, Lisa ^k   Zetterberg, Henrik ^b,l  

^a ALZHEIMER'S ASSOCIATION   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c BRISTOL MYERS SQUIBB   (United States)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e Meso Scale Discovery   (United States)

^f INNOGENETICS   (Belgium)

^g SALADAX BIOMEDICAL INC   (United States)

^h Roche Diagnostics Corporation   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j CRITICAL PATH INSTITUTE   (United States)

^k UCL Institute of Neurology ^*

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Alzheimer's disease; Assay development; Biomarkers; Cerebral spinal fluid; Early diagnosis; Precompetetive; Standardization

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; GANTENERUMAB; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CROSS REACTION; DIAGNOSTIC TEST; HUMAN; IMMUNOASSAY; MEASUREMENT; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUALITY CONTROL; STANDARD; STANDARDIZATION; TRAUMATIC BRAIN INJURY;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; EARLY DIAGNOSIS; HUMANS; REFERENCE STANDARDS;

EID: 84875366315     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2012.11.003     Document Type: Article

References (8)

1. G.M. McKhann, D.S. Knopman, H. Cherkow, B.T. Hyman, C.R. Jack Jr., and C.H. Kawas The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup Alzheimer Dement 7 2011 263 269
2. M. Bjerke, E. Portelius, L. Minthon, A. Wallin, H. Anckarsäter, and R. Anckarsäter Confounding factors influencing amyloid beta concentration in cerebrospinal fluid Int J Alzheimers Dis 2010 986310
3. P. Lewczuk, G. Beck, G. Gandslandt, H. Esselmann, F. Deisenhammer, and A. Regeniter International quality control survey of neurochemical dementia diagnostics Neurosci Lett 409 2006 1 4
4. N.A. Verwey, W.M. van der Flier, K. Blennow, C. Clark, S. Sokolow, and P.P. De Deyn A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease Ann Clin Biochem 46 2009 235 240
5. N. Mattsson, U. Andreasson, M.C. Carrillo, S. Persson, L.M. Shaw, and I. Zegers Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers Biomark Med 6 2012 401 407
6. N. Mattsson, I. Zeegers, U. Andreasson, M. Bjerke, M.A. Blankenstein, and R. Bowser Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid beta42 Biomark Med 6 2012 409 417
7. A. Burton Big science for a big problem: ADNI enters its second phase Lancet Neurol 10 2011 206 207
8. N. Mattsson, U. Andreasson, S. Persson, S. Arai, S.D. Batish, and S. Bernardini The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers Alzheimers Dement 7 2011 386 395